Vifor Pharma Group ’s goal of becoming a world leader in nephrology has moved closer with the expansion of its pact with Cara Therapeutics, Inc. of the US which extends the Swiss group's rights to Korsuva, the partners' soon-to-be filed therapy for dialysis patients with chronic kidney disease-associated pruritus (CKD-aP).
The deal, which could be worth up to $440m follows an alliance inked in 2018 in which the joint venture Vifor Fresenius Medical Care Renal Pharma Ltd. bagged the worldwide rights to the intravenous therapy Korsuva (difelikefalin) excluding the US, Japan and South Korea, as well in dialysis clinics run by Fresenius Medical Care AG & Co. KGaA (FMC) in the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?